"Obesity contributes to worsening heart failure, and while tirzepatide causes considerable weight loss, research is lacking ...

SUMMT has shown for the first time that a drug can reduce major heart failure clinical outcomes in patients with heart ...

CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...

HF specialists agree these drugs will be key tools in fighting the obesity-related HFpEF epidemic. Hurdles and questions ...

The popular weight loss drugs have also been found to reduce other risks, including the risk of death from COVID-19.

Ozempic, Wegovy and other GLP-1 drugs have been shown to curb alcoholism, a new study suggests. Researchers explain why ...

But the agency said later it was re-evaluating the decision that the shortage is over amid litigation, putting compounding of ...

A new study has found that the groundbreaking new class of weight loss drugs may not only be good at treating diabetes, but ...

The study examined GLP-1 drugs, which include semaglutide and tirzepatide. Semaglutide is a key ingredient in Ozempic and Wegovy. Wegovy and Ozempic have also been found to reduce other risks ...

But the agency said later it was re-evaluating the decision that the shortage is over amid litigation, putting compounding of tirzepatide into a gray area. Meanwhile, semaglutide remains on the ...